Barrington James’ Post

Exciting news for BJ!

6 years of trading ✅ 29% revenue growth vs 2022 ✅ 100% candidate retention ✅ Employee landmarks hit ✅ New hires welcomed in ✅ Safe to say 2023 has been a good year for the Clinical Selection - Medical Devices, Life Science, Pharmaceutical & Healthcare Recruitment team. Hats off to James & the wider team for everything they've done this year & I know I speak on behalf of the wider Isotope team when I say what a pleasure it's been to work in & around the business this year. Here's to 2024 📈 & beyond. #recruitmentstartup #recruitmentinvestment #recruitmentbusinesssupport #recruitmentbusinesssetup #businesstips #recruitmentstartuptips

Biopharma Site Selection Goes beyond Location, Location, Location Even in the current challenging market, dozens of biopharma companies are looking for additional space to accommodate operations that are growing or expected to grow. At the same time, some companies are looking to downsize their digs. Whether they plan to expand or contract their laboratories and offices, biopharma companies are weighing many more factors than the one cited in that old saw about real estate. You know: location, location, location. https://ow.ly/6juf50Qmbg1

🚀 Streamlining R&D Sourcing in CRO & CDMO Operations within the Life Sciences Industry 🚀 In the dynamic and ever-evolving landscape of the life sciences industry, the speed of research and development (R&D) is not just an advantage; it's a necessity. As we navigate through the complexities of bringing groundbreaking discoveries from bench to bedside, the efficiency of R&D sourcing becomes a pivotal factor in maintaining a competitive edge and accelerating the pace of innovation. 🔍 Efficiency in Research Sourcing: The Game Changer We are at the forefront of transforming R&D sourcing for Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) by leveraging the power of a centralized platform. This platform revolutionizes how researchers find, compare, and procure a vast array of research services and products. By dramatically reducing the time and effort traditionally associated with sourcing research services, we are not just streamlining processes; we're catalyzing the speed of scientific discovery and development. This efficiency is more than a mere operational improvement; it's a strategic advantage in the fast-paced scientific research sector. The ability to quickly mobilize the right resources and expertise can significantly impact a project's success, driving innovation and ensuring that new therapies and solutions reach those who need them most, faster than ever before. 💡 Why It Matters In a sector where time is of the essence, and the race to innovate defines the future, simplifying and accelerating the procurement process is not just beneficial; it's critical. Our platform is designed to empower CROs and CDMOs by: Enhancing access to a diverse range of high-quality services and technologies Facilitating informed decision-making through comparative insights Reducing administrative burdens, allowing researchers to focus on their core scientific pursuits 🌍 A Call to Action for Industry Leaders As we continue to push the boundaries of what's possible in the life sciences industry, embracing innovative solutions for R&D sourcing is not just an option; it's a necessity for survival and success. Let's champion the efficiency and speed of research sourcing to fuel the next wave of scientific breakthroughs and therapeutic advancements. Together, we can redefine the landscape of R&D sourcing in the life sciences industry, setting a new standard for efficiency, innovation, and success. #LifeSciences #Innovation #RnD #CRO #CDMO #ResearchSourcing #ScientificResearch

After a challenging period for the industry, are we seeing green shoots? In this article, the latest instalment of the Talent Hub from The Evidence Base®, Martin Anderson (Founding Director, Carrot Recruitment) looks at this from the point-of-view of market sentiment. #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #regulation #regulatoryaffairs #hta #healthtechnologyassessment #healthdata #healthequity #healthpolicy

The commercialization process in the life sciences industry is complex and ever-changing. To succeed in this environment, companies need to be agile and adaptable. Staffing providers can play a key role in helping life sciences companies reshape the commercialization process. #LifeSciences #Staffing #WorkforceManagement

In today’s instalment of our research and development (R&D) series, we’re discussing the importance of strategic partnerships within Life Sciences.   To learn more on how regulatory collaborations improve access and Alliances accelerate speed to market, read our insight piece below.   #lifesciences #researchanddevelopment #strategicpartnerships #alliances 

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Resilience plans to expand Ohio facility with 440 new jobs over three years: National Resilience is expanding its operations in West Chester, OH, to “nearly double” its capacity. The company is adding 440 new jobs across its manufacturing engineering, quality control, internet technology and management divisions. According to a Monday press release, the new hires will take place over the next three years; 274 will be direct employees, and 166 will be contractors. In a release in January, the company noted the site has around 500 workers. Earlier this year, Resilience laid off employees at a manufacturing site in Massachusetts. Endpoints News enquired if the company has laid off employees at any of its sites in the past three months. While the company declined to provide details, CEO Rahul Singhvi replied in an email: At Resilience, we continuously assess our operations to align with market realities and our customers’ needs. This includes balancing our resources across our network by reducing roles in some areas while adding positions in others, based on demand. While this is a difficult decision, it is a necessary step for the company to serve customer’s and patient’s needs more effectively. Resilience purchased the West Chester site from AstraZeneca in January. The companies entered a multi-year deal where Resilience took over manufacturing AstraZeneca’s products at this same site. The 580,000-square-foot facility is equipped for aseptic filling, packaging, labeling and cold-chain operations for vials, cartridges, pre-filled syringes and autoinjectors. Since its launch in 2020, Resilience has set up operations at 11 locations in North America, including its headquarters in San Diego, and has manufacturing capabilities across cell and gene therapy, biologics, nucleic acids and vaccines. #lucidquest #genetherapy #celltherapy

Gene&Cell Therapy >> Resilience plans to expand Ohio facility with 440 new jobs over three years: National Resilience is expanding its operations in West Chester, OH, to “nearly double” its capacity. The company is adding 440 new jobs across its manufacturing engineering, quality control, internet technology and management divisions. According to a Monday press release, the new hires will take place over the next three years; 274 will be direct employees, and 166 will be contractors. In a release in January, the company noted the site has around 500 workers. Earlier this year, Resilience laid off employees at a manufacturing site in Massachusetts. Endpoints News enquired if the company has laid off employees at any of its sites in the past three months. While the company declined to provide details, CEO Rahul Singhvi replied in an email: At Resilience, we continuously assess our operations to align with market realities and our customers’ needs. This includes balancing our resources across our network by reducing roles in some areas while adding positions in others, based on demand. While this is a difficult decision, it is a necessary step for the company to serve customer’s and patient’s needs more effectively. Resilience purchased the West Chester site from AstraZeneca in January. The companies entered a multi-year deal where Resilience took over manufacturing AstraZeneca’s products at this same site. The 580,000-square-foot facility is equipped for aseptic filling, packaging, labeling and cold-chain operations for vials, cartridges, pre-filled syringes and autoinjectors. Since its launch in 2020, Resilience has set up operations at 11 locations in North America, including its headquarters in San Diego, and has manufacturing capabilities across cell and gene therapy, biologics, nucleic acids and vaccines. #lucidquest #genetherapy #celltherapy

Learn more about our SPEO Model and how we operationalize it to cost and resource optimize your drug development journey. Bullpen #CRO #biotechnology #pharmaceuticalsindustry #sponsor #Sites